Steven Nathan on Big Pharma: Aspen and Ascendis

10X founder Steven Nathan shares his pearls of wisdom on interesting developments taking place across local and international markets. Since his departure at 10X at the beginning of the year, Nathan has been on ‘garden leave’, which is a restraint of trade prohibiting him from working in the asset management industry for two years. Despite calling his time off “refreshing”, Nathan says it’s important to not lose focus and hence has been keeping up to date with all the market trends in 2021. Local talking points include Northam Platinum’s R17bn deal with Royal Bafokeng Platinum; representative of the Ascendis Activist Investors (Harry Smit) being appointed to the board of directors; and Mark Sardi departing the debt-laden pharma business for South Africa’s pharma leader, Aspen. Learn more about your ad choices. Visit megaphone.fm/adchoices